Tilvestamab is a humanized anti-AXL function blocking monoclonal antibody. Tilvestamab inhibited AXL activation induced by Gas6 stimulation in vitro. Tilvestamab inhibited the progression of tumors induced by the orthotopically implanted 786-0 renal cell carcinoma cells.